Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer

Cristina Guarducci(Hospital of Prato), Ilenia Migliaccio(Hospital of Prato)

npj Breast Cancer

November 22, 2018

10.1038/s41523-018-0092-4

Cited by 134

Related Papers

Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase

|Cell|2011|276

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

|Clinical Cancer Research|2011|181

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer

|Oncotarget|2016|170

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

|Molecular Cancer Research|2016|49

Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer

|Clinical Cancer Research|2024|34